VILLA GUARDIA (COMO), Italy, June 21, 2011 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced that the Company has signed a ten-year exclusive license and distribution agreement with Medison Pharma Ltd. for defibrotide in Israel and the Palestinian Authority. Under the terms of the agreement, Medison will be responsible for managing the named-patient sales program and for local registration, authorization, marketing, reimbursement, and medical affairs in Israel and the Palestinian Authority region. Following approval to market defibrotide, if any, Medison will have the exclusive right to promote, purchase, market and sell defibrotide in these territories.
